Literature DB >> 10352088

High dose omeprazole plus amoxicillin and azithromycin in eradication of Helicobacter pylori in duodenal ulcers.

A Vcev1, D Stimac, A Vceva, B Takac, D Pezerovíc, A Ivandíc.   

Abstract

BACKGROUND: The aim of our study was to establish whether one-week triple therapy regimen (omeprazole, amoxicillin, azithromycin) with low dose (2 x 20 mg/day) or high dose omeprazole (2 x 40 mg/day) is more effective in curing H. pylori infection in patients with active duodenal ulcer disease.
METHODS: One hundred and twenty patients with duodenal ulcer and H. pylori infection were treated with amoxicillin 2 x 1000 mg/day for the first 7 days plus azithromycin 500 mg/day for the first 6 days. Patients were randomly assigned to receive either omeprazole 2 x 20 mg/day for the first 7 days (group A; n = 60) or omeprazole 2 x 40 mg/day for the first 7 days (group B; n = 60). After 7 days all patients in both groups continued treatment with omeprazole (40 mg/day (days 8-14) and 20 mg/day (days 15-28)). H. pylori status was determined by urease test and histology before the treatment and 4 weeks after cessation of any medication.
RESULTS: One hundred and thirteen patients completed the study. H. pylori infection was eradicated in 73.2% [41/56] of patients in group A (intention-to-treat [ITT] analysis: 68.3%; 95% CI: 58.6-80.4%) vs. 82.5% [47/57] of patients in group B (ITT analysis: 78.3%; 95% CI: 67.8-87.9%; NS). All ulcers had healed after 4 weeks of omeprazole treatment. Side effects, usually minor, were recorded in 12.5% (group A) and in 14% (group B) of patients (NS), but therapy was discontinued for only one patient in group B (NS).
CONCLUSION: There was no statistically significant difference between one-week triple therapy regimen (omeprazole, amoxicillin, azithromycin) with high dose omeprazole (2 x 40 mg/day) and regimen with low dose omeprazole (2 x 20 mg/day) in curing H. pylori infection in patients with active duodenal ulcer disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10352088     DOI: 10.1046/j.1523-5378.1999.09041.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  5 in total

1.  Comparison of half-dose and full-dose triple therapy regimens for Helicobacter pylori eradication in patients with end-stage renal disease.

Authors:  Mohammad Javad Ehsani Ardakani; Mohammad Aghajanian; Amir Ahmad Nasiri; Hamid Mohaghegh-Shalmani; Homayoun Zojaji; Iradj Maleki
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2014

2.  Pharmacoeconomic comparison of Helicobacter pylori eradication regimens.

Authors:  Mesut Sancar; Fikret Vehbi Izzettin; Sule Apikoglu-Rabus; Fatih Besisik; Nurdan Tozun; Gul Dulger
Journal:  Pharm World Sci       Date:  2006-10-26

3.  Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: a meta-analysis.

Authors:  Jie Dong; Xiao-Feng Yu; Jian Zou
Journal:  World J Gastroenterol       Date:  2009-12-28       Impact factor: 5.742

4.  Azithromycin in a triple therapy for H.pylori eradication in active duodenal ulcer.

Authors:  Vladimir T Ivashkin; Tatiana L Lapina; Oksana Yu Bondarenko; Olga A Sklanskaya; Petr Ya Grigoriev; Yuri V Vasiliev; Emilia P Yakovenko; Pavel V Gulyaev; Valeri I Fedchenko
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

5.  Comparison of azithromycin and clarithromycin triple therapy regimens for helicobacter pylori eradication in hemodialysis patients.

Authors:  Mojgan Jalalzadeh; Morteza Nazarian; Jamshid Vafaeimanesh; Fatemeh Mirzamohammadi
Journal:  Nephrourol Mon       Date:  2012-06-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.